CD8A and neoplasm: Recent findings highlight its therapeutic potential, especially in colon cancer, where acetate therapy has been shown to inhibit the expression of the immunological checkpoint ligand PVR/CD155, thereby enhancing the effector responses of CD8+ T cells and potentially boosting anti-tumor immunity.